Bristol Myers Squibb has increased its growth assets to 58.2% of total revenues, showing strong portfolio renewal and slowing decline in legacy products. Key drug launches like iberdomide and mezigdomide target multiple myeloma, supporting raised 2026 guidance and margin expansion. The company’s strong cash flow underpins a secure dividend and improved balance sheet, making it a recommended buy on price dips for long-term gains. Overall, Bristol Myers Squibb is positioned for double-digit upside with a robust pipeline and valuation re-rating potential.
Bristol Myers Squibb (BMY) is currently trading at a 51% discount to the sector median, presenting a strong buy opportunity due to its compelling risk/reward profile. The company achieved 15% year-over-year revenue growth driven by its growth portfol...
Alexandria Real Estate Equities, a leading life science real estate company, marked Blood Cancer Awareness Month by spotlighting its investments and tenants developing treatments for blood cancers like leukemia and lymphoma. The company emphasized it...
Bristol Myers Squibb (BMY) is considered undervalued, trading at a forward P/E of 9.8x with a 3.7% dividend yield. Its growth portfolio now accounts for nearly 60% of revenue, helping offset declines in legacy drugs and supporting 5% year-over-year r...
RBC Capital Markets reaffirmed its 'outperform' rating on Oxford BioMedica, despite clinical trial pauses by partners Novartis and BMS. The broker views the trial halts as having limited financial impact, with only £10-16 million in annual clinical r...
The Health Care Select Sector SPDR Fund (XLV) offers broad healthcare exposure but delivers a low dividend yield around 1.5% due to its cap-weighted structure favoring large, lower-yield stocks like Eli Lilly. Directly owning top XLV holdings AbbVie,...
